Skip to main content
Clinical Trials/NCT05421819
NCT05421819CompletedNot Applicable

Design and Development of a Novel Food Supplement for Osteoporosis Based on Gut Microbiome Mechanisms: Efficacy and Tolerability Assessment

National and Kapodistrian University of Athens1 site in 1 country117 target enrollmentStarted: June 15, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
117
Locations
1
Primary Endpoint
Bone geometry

Study Overview

Brief Summary

It is well proven that the intestinal microbe regulates bone metabolism by the absorption of calcium and other metallic trace elements. Studies also show that regulation of the intestine and its microbe can affect bone density and resistance to a variety of animal models and humans. At the same time, interest in polyphenol-intestinal microbial interactions and in particular flavonoids and catechins has increased. Indeed, it has been observed that they are transformed via the microbe into bioactive compounds, and polyphenols themselves can modify the synthesis of the intestinal microbe.

OSTEOME aspires to design and develop a novel dietary supplement for osteoporosis, activating the intestinal microbiome. At the same time companion biomarkers will be studied related to the efficacy and tolerability of the new supplement. The selection of flavonoids will take place through in vitro and in silico studies focusing on their interaction with pathways that regulate the activity of osteoclasts and osteoblasts. The efficacy and tolerability of the dietary supplement will be evaluated through a randomized clinical intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
50 Years to 70 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Postmenopausal women
  • •T-score in the osteopenic range (-1.0 > T-score > -2.5) at either the lumbar spine (LS) or femur as measured by dual energy X-ray absorptiometry (DXA)

Exclusion Criteria

  • •T-score in the osteoporotic range (T-score < -2.5) at any site
  • •Patients receiving supplements of calcium and/or vitamin D at that time or during the last 6 months
  • •Patients receiving medications known to positively or negatively affect bone turnover or BMD at that time or during the last 3 years (e.g. antiresorptive agents, oestrogens, systemic corticosteroids), or
  • •Secondary cause of osteoporosis (e.g. alcohol abuse, thyrotoxicosis etc)
  • •Patients who did not attend to their follow-up appointment and consequently had only the baseline measurements

Arms & Interventions

Calcium and vitamin D supplement

Active Comparator

In this arm, 50 women will receive calcium and vitamin D supplement once per day.

Intervention: Calcium and vitamin D supplement (Dietary Supplement)

Calcium, vitamin D and prebiotic supplement

Active Comparator

In this arm, 50 women will receive calcium, vitamin D and prebiotic supplement once per day.

Intervention: Calcium, vitamin D and prebiotic supplement (Dietary Supplement)

Calcium, vitamin D, prebiotic and flavonoid supplement

Active Comparator

In this arm, 50 women will receive calcium, vitamin D, prebiotic and flavonoid supplement once per day.

Intervention: Calcium, vitamin D and flavonoid supplement (Dietary Supplement)

Outcomes

Primary Outcomes

Bone geometry

Time Frame: 0 to 12 months

The primary endpoint is the within and between group change of bone geometry after 12 months of supplementation assessed by peripheral quantitative computed tomography (pQCT) of the tibia

Secondary Outcomes

  • Areal bone mineral density (aBMD), trabecular bone score (TBS), adverse effects (tolerability) and adherence to dietary supplement after 12 months(12 months)
  • Bone turnover markers, PINP and CTX(3, 6 and 12 months)
  • Change of serum TNF-α, IL-1, OPG, RANKL and IGF-1(3, 6 and 12 months)
  • Change of microMR1 Change of serum miRNAs(3, 6 and 12 months)
  • Change of gut microbiota(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

EFSTATHIOS CHRONOPOULOS

Associate Professor in Orthopaedics at National and Kapodistrian University of Athens, Laboratory for Research of the Musculoskeletal System Director

National and Kapodistrian University of Athens

Study Sites (1)

Loading locations...

Similar Trials

Design and Development of a Novel Food... | Clinical Trial